Alopecia Areata Video Perspectives

Emma Guttman-Yassky, MD, PhD

Guttman-Yassky reports financial relationships with AbbVie, Almirall, Amgen, AnaptysBio, Arena, Asana Biosciences, Aslan Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Bristol Meyers Squibb, Cara Therapeutics, Celgene, Connect Pharma, Eli Lilly, EMD Serono, Evidera, Galderma, Ichnos Sciences, Incyte, Innovaderm, Janssen Biotech, Kyowa Kirin, LEO Pharma, Novartis, Pandion Therapeutics, Pfizer, RAPT Therapeutics, Regeneron Pharmaceuticals, Sanofi, SATO Pharmaceutical, Siolta Therapeutics, Target Pharma Solutions, UCB and Ventyx Biosciences.
October 11, 2023
1 min watch
Save

VIDEO: Limited treatment options for alopecia areata create challenges

Transcript

Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

Even in adults, we currently have nothing approved as you know, but in adults there are studies going on, and there are some studies also going on in adolescents 12 and up. But in children, we really have nothing. And in clinical practice, so, you know, we have injections of steroids. We have some topical sensitizers, DPCP that are messy, not so helpful for many patients and then, we have off-label drugs that are being used, such as cyclosporine, immune suppressants basically, cyclosporine, other immune suppressants, even oral prednisone. Some people use JAK inhibitors from other indications and we have some, studies with JAK inhibitors that are going now into alopecia. And there are also some studies, clinical trials of course, with biologics.